Quark Pharmaceuticals announced it has developed proprietary siRNA structures that it claims will enable it to develop drug candidates based entirely on its own intellectual property. The company has, however, disclosed few details about the molecules.

"We no longer need to rely on other people's patents as far as the structure of the siRNA," says Quark CEO Danny Zurr. Patent applications covering the structures are completely owned by Quark and "we have ascertained through two independent … IP law firms that, indeed, we have the freedom to operate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.